Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 26;12:277–292. doi: 10.2147/OARRR.S265806

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tahir et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ASAS20 and ASAS40 line graphs showing response rates with secukinumab 150 mg through 5 years in MEASURE 1.³⁷

Notes: Data shown are as observed through 5 years for patients who entered the three-year extension study after the initial two-year study, and do not include placebo switchers or patients whose dose was escalated. Reproduced from Baraliakos X et al. Long-term efficacy andsafety of secukinumab 150 mg in ankylosing spondylitis: 5-yearresults from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005, © 2019. With permission from BMJ Publishing Group Ltd.

Abbreviations: ASAS, Assessment of SpondyloArthritis international Society response criteria.